LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for Feb. 19 at Morehouse College in Atlanta. The Summit, inspired by the music and legacy of De La Soul, brings together leaders in health, culture, science, and community to advance health equity for Black men and families. It is rooted in De La Soul’s song “Good Health,” written following the passing of founding member David Jolicoeur (Trugoy the Dove).
Developed in collaboration with Blacksmith holdings, the program reflects De La Soul’s evolution from musical pioneers to wellness advocates. Discussions will span cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness. LIXTE said the Summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA, while creating a space to connect scientific innovation with communities most impacted by health disparities.
To view the full press release, visit https://ibn.fm/0kkqK.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology - activation lethality - that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer.
